BACKGROUND: The improvement in survival rates for patients with colon cancer has shifted the focus from examining cancer-specific mortality to exploring all-cause mortality. Adverse events such as venous thromboembolism (VTE) affect overall survival times and the net clinical benefit of cancer management strategies. METHODS: This retrospective study used Surveillance, Epidemiology and End Results (SEER) Medicare data to examine VTE incidence and mortality rates for elderly patients with stage III colon cancer who were diagnosed in 2004 or 2005 and followed through 2007. The impact of VTE on mortality was estimated using multivariable Cox proportional hazards regression. RESULTS: In all, 20.7% of 4,985 elderly patients with stage III colon cancer had clinically diagnosed VTE following diagnosis. All-cause mortality risk was higher for patients with a VTE diagnosis (hazard ratio [HR]: 1.15, 95% confidence interval [CI]: 1.04-1.27), greater comorbidity burden, more advanced tumor depth and nodal involvement within stage III, advanced age, and male sex; the risk was lower for patients treated with chemotherapy. VTE was associated with higher mortality hazards (HR: 1.41, 95% CI: 1.21-1.64) for patients treated with adjuvant chemotherapy but not for untreated patients. CONCLUSIONS: A new diagnosis of VTE significantly reduced survival rates for elderly patients with stage III colon cancer and further reduced survival rates for patients treated with chemotherapy. Improved prevention and management of VTE for elderly patients with stage III colon cancer who are at risk for VTE is warranted, particularly for patients treated with chemotherapy.
BACKGROUND: The improvement in survival rates for patients with colon cancer has shifted the focus from examining cancer-specific mortality to exploring all-cause mortality. Adverse events such as venous thromboembolism (VTE) affect overall survival times and the net clinical benefit of cancer management strategies. METHODS: This retrospective study used Surveillance, Epidemiology and End Results (SEER) Medicare data to examine VTE incidence and mortality rates for elderly patients with stage III colon cancer who were diagnosed in 2004 or 2005 and followed through 2007. The impact of VTE on mortality was estimated using multivariable Cox proportional hazards regression. RESULTS: In all, 20.7% of 4,985 elderly patients with stage III colon cancer had clinically diagnosed VTE following diagnosis. All-cause mortality risk was higher for patients with a VTE diagnosis (hazard ratio [HR]: 1.15, 95% confidence interval [CI]: 1.04-1.27), greater comorbidity burden, more advanced tumor depth and nodal involvement within stage III, advanced age, and male sex; the risk was lower for patients treated with chemotherapy. VTE was associated with higher mortality hazards (HR: 1.41, 95% CI: 1.21-1.64) for patients treated with adjuvant chemotherapy but not for untreated patients. CONCLUSIONS: A new diagnosis of VTE significantly reduced survival rates for elderly patients with stage III colon cancer and further reduced survival rates for patients treated with chemotherapy. Improved prevention and management of VTE for elderly patients with stage III colon cancer who are at risk for VTE is warranted, particularly for patients treated with chemotherapy.
Authors: John A Heit; W Michael O'Fallon; Tanya M Petterson; Christine M Lohse; Marc D Silverstein; David N Mohr; L Joseph Melton Journal: Arch Intern Med Date: 2002-06-10
Authors: T E Le Voyer; E R Sigurdson; A L Hanlon; R J Mayer; J S Macdonald; P J Catalano; D G Haller Journal: J Clin Oncol Date: 2003-08-01 Impact factor: 44.544
Authors: Hans-Martin M B Otten; Joost Mathijssen; Hugo ten Cate; Marcel Soesan; Marijke Inghels; Dick J Richel; Martin H Prins Journal: Arch Intern Med Date: 2004-01-26
Authors: Paolo Prandoni; Anthonie W A Lensing; Andrea Piccioli; Enrico Bernardi; Paolo Simioni; Bruno Girolami; Antonio Marchiori; Paola Sabbion; Martin H Prins; Franco Noventa; Antonio Girolami Journal: Blood Date: 2002-07-12 Impact factor: 22.113
Authors: N Alhassan; M Trepanier; C Sabapathy; P Chaudhury; A S Liberman; P Charlebois; B L Stein; L Lee Journal: Tech Coloproctol Date: 2018-12-19 Impact factor: 3.781
Authors: Steven Ades; Bhargavi Pulluri; Chris E Holmes; Inder Lal; Santosh Kumar; Benjamin Littenberg Journal: Cancer Med Date: 2022-02-06 Impact factor: 4.711
Authors: Dae Sik Kim; Keun-Myoung Park; Yong Sung Won; Jang Yong Kim; Jin Kwon Lee; Jun Gi Kim; Seong Taek Oh; Sang Seol Jung; Won Kyung Kang Journal: Vasc Specialist Int Date: 2014-06-30
Authors: Sandro Barni; Gerardo Rosati; Sara Lonardi; Nicoletta Pella; Maria Banzi; Maria G Zampino; Katia F Dotti; Lorenza Rimassa; Paolo Marchetti; Evaristo Maiello; Fabrizio Artioli; Daris Ferrari; Roberto Labianca; Paolo Bidoli; Alberto Zaniboni; Alberto Sobrero; Vincenzo Iaffaioli; Sabino De Placido; Gian Luca Frassineti; Andrea Ciarlo; Angela Buonadonna; Nicola Silvestris; Elena Piazza; Lorenzo Pavesi; Mauro Moroni; Mario Clerico; Massimo Aglietta; Paolo Giordani; Francesca Galli; Fabio Galli; Fausto Petrelli Journal: Ther Adv Med Oncol Date: 2020-01-20 Impact factor: 8.168